JB Chemicals & Pharmaceuticals (506943) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 revenue grew 14% year-over-year to INR 963 crore, with net profit up 22% to INR 162 crore and operating EBITDA up 15% to INR 270 crore, driven by strong domestic and CDMO business momentum.

• Domestic business contributed 59%-60% of revenue, growing 22% year-over-year, outpacing the Indian pharma market (IPM) growth of 8%.

• International business grew 4% year-over-year in Q3 FY25, with CDMO segment leading at 33% growth; U.S. and Russia saw challenges, but South Africa and branded generics performed well.

• Standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2024, were approved by the Board and reviewed by auditors, with no material misstatements identified.

• Interim dividend of ₹8.5 per equity share declared, with record date set for February 8, 2025.

Financial highlights

• Gross margin for Q3 stood at 67.1%, slightly down from 67.6% last year; cost optimization and favorable product mix supported margin expansion.

• Operating EBITDA margin improved to 28.1% in Q3 FY25; finance costs reduced to INR 3 crore from INR 12 crore year-over-year due to lower gross debt.

• Net cash position was INR 516 crore as of December 2024; gross debt reduced to INR 54 crore.

• Standalone and consolidated net profit after tax for Q3 FY25 was ₹15,639 lakhs and ₹16,249 lakhs, respectively, both up year-over-year.

• Basic EPS (consolidated) for Q3 FY25 was ₹10.46, up from ₹8.62 in Q3 FY24.

Outlook and guidance

• Operating margins are expected to remain between 26%-28% despite inflation and market uncertainties.

• Q4 is expected to deliver double-digit growth in international business and strong CDMO performance; India may be softer due to March inventory trends.

• India and CDMO businesses projected to constitute 75–80% of total revenue mid-term.

• Gross margins are expected to remain in the 66%-67% range, with potential for improvement if product mix and market conditions remain favorable.

• The company continues to focus on its core pharmaceuticals segment and has declared an interim dividend, indicating confidence in ongoing performance.